The effect of Lubiprostone for MMC patients

The effect of Lubiprostone for MMC patients - The effect of Lubiprostone for MMC patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023159

Enrollment

Registered

2016-07-14

Start date

2016-07-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spina bifida

Interventions

Three months Lubiprostone 24 micro g 2T/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients from whom we have received written consent.

Exclusion criteria

Exclusion criteria: Any other patients who are regarded as unsuitable for this study by the investigator.

Design outcomes

Primary

Measure	Time frame
Constipation scoring system (CSS)	—

Secondary

Measure	Time frame
status of defecation, QOL	—

Countries

Japan

Contacts

Public ContactTakeya Kitta

Hokkaido University Graduate School of Medicine Department of Renal and Genitourinary surgery

kitta@fb3.so-net.ne.jp011-706-5966

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026